India Patent Office Weighs Cipla, Natco Challenges To Bayer’s Nexavar
This article was originally published in PharmAsia News
India’s Mumbai Patent Office is expected to decide soon whether Bayer’s Nexavar (sorafenib) for treating liver and kidney cancers can be allowed on the market in generic form.
You may also be interested in...
A flurry of financial appointments has been seen across the off-patent industry, involving major players Dr Reddy’s, Biocon, Mayne Pharma and Xbrane Biopharma.
Aurobindo has agreed to sell its US-based Natrol dietary supplements business at a significant premium to the $132.5m it paid in late 2014, as the Indian firm continues to drive into complex formulations in the US, including injectables and biosimilars.
GlaxoSmithKline’s third quarter results included a 9% decline in sales in its vaccine business, but this was offset by tight cost controls and restructuring benefits; the company expects to continue investing in its pipeline and new product launches.